Leidos price target raised to $136 from $124 at Citi

Citi raised the firm’s price target on Leidos to $136 from $124 and keeps a Buy rating on the shares. The company’s Q3 results were ahead of consensus expectations driven largely by ramping programs in the healthcare segment and successful achievement of incentive fees on past work, the analyst tells investors in a research note. The firm says a “cleaner story continues to emerge.”